Pharma — Maj 2024
-
ALK får sat kursmålet op med en femtedel af Jefferies https://www.proinvestor.com/chathistory/-167/gubra
-
Lundbeck flyvende fra start i 2024 trods bump på vejen for nøgleprodukt https://www.proinvestor.com/investornyt/1159953/lundbeck-flyvende-fra-start-i-2024-trods-bump-pa-vejen-for-nogleprodukt
-
AstraZeneca To Build $1.5 Bln Manufacturing Facility In Singapore For Antibody Drug Conjugates https://www.proinvestor.com/investornyt/1161783/astrazeneca-to-build-15-bln-manufacturing-facility-in-singapore-for-antibody-drug-conjugates
-
ALK har søgt om godkendelse af tablet mod træpollenallergi i børn og unge https://proinvestor.com/investornyt/1166430/alk-har-sogt-om-godkendelse-af-tablet-mod-traepollenallergi-i-born-og-unge
-
Novartis: Phase III Data On Oral Remibrutinib Shows Long-Term Efficacy & Safety In Chronic Urticaria https://proinvestor.com/investornyt/1166865/novartis-phase-iii-data-on-oral-remibrutinib-shows-long-term-efficacy-amp-safety-in-chronic-urticaria
-
iogen : EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis https://proinvestor.com/investornyt/1166862/biogen-eu-approves-qalsody-to-treat-rare-genetic-form-of-amyotrophic-lateral-sclerosis
-
FDA Acknowledges Astellas Pharma's Resubmission Of BLA For Zolbetuximab https://proinvestor.com/investornyt/1166867/fda-acknowledges-astellas-pharmas-resubmission-of-bla-for-zolbetuximab
-
Gilead : Phase 3 Study Of Trodelvy In Metastatic Urothelial Cancer Fails To Meet Primary Endpoint https://proinvestor.com/investornyt/1166858/gilead-phase-3-study-of-trodelvy-in-metastatic-urothelial-cancer-fails-to-meet-primary-endpoint
-
Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients https://proinvestor.com/investornyt/1166894/sanofi-regeneron-dupixent-recommended-for-eu-approval-by-chmp-to-treat-copd-patients
-
Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month https://proinvestor.com/investornyt/1166896/regeneron-fda-extends-review-period-for-dupixent-as-copd-treatment-by-three-month
-
AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis https://proinvestor.com/investornyt/1166910/abbvie-risankizumab-recommended-for-eu-approval-for-moderately-severely-active-ulcerative-colitis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind